Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan

被引:1
|
作者
Narita, Aya [1 ]
Koto, Yuta [2 ]
Noto, Shinichi [3 ]
Okada, Masafumi [4 ]
Ono, Midori [5 ]
Baba, Terumi [5 ]
Sagara, Rieko [5 ]
Sakai, Norio [6 ]
机构
[1] Tottori Univ, Div Child Neurol, Inst Neurol Sci, Fac Med, Yonago, Japan
[2] Osaka Aoyama Univ, Fac Hlth Sci, Sch Nursing, Osaka, Japan
[3] Niigata Univ Hlth & Welf, Dept Rehabil, Niigata, Japan
[4] IQVIA Solut Japan KK, Real World Evidence Solut & HEOR, Tokyo, Japan
[5] Takeda Pharmaceut Co Ltd, Japan Med Off, Tokyo, Japan
[6] Osaka Univ, Grad Sch Med, Div Hlth Sci, Child Healthcare & Genet Sci Lab, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Gaucher disease; Japan; Patient reported outcome measures; Quality of life; Burden of disease; Neuronopathic Gaucher disease; Reliability; Validity;
D O I
10.1186/s13023-023-02996-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Patients with Gaucher disease (GD), a rare lysosomal storage disorder, have reduced health-related quality of life (HRQOL). A patient-reported outcome measure (PROM) for HRQOL developed for type 1 GD (GD1) is not appropriate for patients with neuronopathic GD (nGD) types 2 (GD2) and 3 (GD3). In this study, we developed a new PROM for use in all GD types. We previously reported the qualitative analysis of interviews with Japanese patients with nGD, which was used to create nGD-specific PROM items. Here we evaluated the full PROM combining the type 1 questionnaire with the new nGD-specific items.Methods Patients with confirmed GD were recruited (Association of Gaucher Disease Patients in Japan or leading doctors) for pre-testing (May 2021) or the main survey (October-December 2021). The PROM had three parts: Parts 1 and 2 were translated into Japanese from the pre-existing GD1 PROM, whereas Part 3 was newly developed. Patients (or their caregivers, where necessary) completed the PROM questionnaire on paper and returned it by mail. Mean scores were determined overall and by GD type. Inter-item correlations, content consistency (Cronbach's alpha), and test-retest reliability (Cohen's kappa; main survey only, taken 2 weeks apart) were calculated.Results Sixteen patients (three with GD1; six with GD2; seven with GD3) and 33 patients (nine with GD1; 13 with GD2; 11 with GD3) participated in the pre-test and main survey, respectively. All GD2 patients and one-third (6/18) of GD3 patients required caregivers to complete the questionnaire. Mean scores indicated that the burden was highest in GD2 and lowest in GD1. In the main survey, internal consistency was high (Cronbach's alpha = 0.898 overall, 0.916 for Part 3), and test-retest reliability was high for Part 3 (kappa > 0.60 for 13/16 items) but low for Part 1 (kappa < 0.60 for 12/15 items).Conclusions We have developed a flexible and reliable PROM that can be tailored for use in all types of GD and propose using Parts 1 and 2 for GD1, Parts 2 and 3 for GD2, and Parts 1, 2, and 3 for GD3.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Development and Validation of the AFSymp™ : An Atrial Fibrillation-Specific Measure of Patient-Reported Symptoms
    Medin, Jennie
    Arbuckle, Rob
    Abetz, Linda
    Halling, Katarina
    Kulich, Karoly
    Edvardsson, Nils
    Coyne, Karin S.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2014, 7 (03): : 319 - 327
  • [32] Development and Validation of the AFSymp™: An Atrial Fibrillation-Specific Measure of Patient-Reported Symptoms
    Jennie Medin
    Rob Arbuckle
    Linda Abetz
    Katarina Halling
    Karoly Kulich
    Nils Edvardsson
    Karin S. Coyne
    The Patient - Patient-Centered Outcomes Research, 2014, 7 : 319 - 327
  • [33] Development of a condition-specific patient-reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire
    Lokhorst, M. M.
    Horbach, S. E. R.
    Young-Afat, D. A.
    Stor, M. L. E.
    Haverman, L.
    Spuls, P. I.
    van der Horst, C. M. A. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (04) : 797 - 803
  • [34] Evaluation of the effect of urethroplasty for anterior urethral strictures by a validated disease-specific patient-reported outcome measure
    Akio Horiguchi
    Masayuki Shinchi
    Kenichiro Ojima
    Ayako Masunaga
    Keiichi Ito
    Tomohiko Asano
    Eiji Takahashi
    Fumihiro Kimura
    Ryuichi Azuma
    World Journal of Urology, 2019, 37 : 601 - 606
  • [35] Evaluation of the effect of urethroplasty for anterior urethral strictures by a validated disease-specific patient-reported outcome measure
    Horiguchi, Akio
    Shinchi, Masayuki
    Ojima, Kenichiro
    Masunaga, Ayako
    Ito, Keiichi
    Asano, Tomohiko
    Takahashi, Eiji
    Kimura, Fumihiro
    Azuma, Ryuichi
    WORLD JOURNAL OF UROLOGY, 2019, 37 (04) : 601 - 606
  • [36] Gaucher disease (GD)-specific patient-reported outcome (PRO) measures for clinical monitoring and for clinical trials
    Elstein, Deborah
    Klemen, Martin
    Panter, Charlotte
    Bonner, Nicola
    Johnson, Chloe
    Zimran, Ari
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S52 - S52
  • [37] Development of the Fabry Disease Patient-Reported Outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry Disease
    Hamed, Alaa
    DasMahapatra, Pronabesh
    Lyn, Nicole
    Gwaltney, Chad
    Hopkin, Robert J.
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [38] Development of the Fabry Disease Patient-Reported Outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry Disease
    Alaa Hamed
    Pronabesh DasMahapatra
    Nicole Lyn
    Chad Gwaltney
    Robert J. Hopkin
    Orphanet Journal of Rare Diseases, 16
  • [39] Sex differences in patient-reported outcome measure of psychotic symptoms in schizophrenia
    Vila-Badia, Regina
    Ochoa, Susana
    Fabrega-Ruz, Julia
    Gonzalez-Caballero, Juan Luis
    Romero, Cristina
    Cid, Jordi
    Frigola-Capell, Eva
    Salvador-Carulla, Luis
    Moreno-Kuestner, Berta
    ARCHIVES OF WOMENS MENTAL HEALTH, 2024, 27 (05) : 721 - 729
  • [40] Patient-reported impact of scars measure (PRISM): development and validation of a new skin scar patient-reported outcome measure
    Brown, B. C.
    McKenna, S. P.
    Solomon, M.
    Wilburn, J.
    McGrouther, D. A.
    Bayat, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 : 17 - 17